Overview
Astellas Pharma Inc. is a Tokyo-headquartered pharmaceutical company that discovers, develops and commercializes medicines. Its stated mission is to turn innovative science into value for patients. Established in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, it operates in more than 70 countries and areas.[1][2]
Astellas’ medicines span oncology, ophthalmology, urology, immunology and women’s health. Its portfolio includes XTANDI, PADCEV and VEOZAH. In the fiscal year ended March 31, 2025, the company reported revenue of approximately ¥1.91 trillion and 13,643 employees.[3][4][5] [1][2][3][4][5]
Products & services
Astellas’ oncology products include XTANDI (enzalutamide), an androgen-receptor inhibitor for prostate cancer, and XOSPATA (gilteritinib), a FLT3 inhibitor for adults with relapsed or refractory acute myeloid leukemia whose cancer has a FLT3 mutation. PADCEV (enfortumab vedotin) is a nectin-4-directed antibody–drug conjugate for urothelial cancer. VYLOY (zolbetuximab) targets CLDN18.2 and is used with chemotherapy for eligible advanced gastric or gastroesophageal-junction cancer.[6][7][8][9]
Outside oncology, Astellas markets mirabegron, a beta-3 adrenergic agonist for overactive bladder, under brands including MYRBETRIQ and BETMIGA. VEOZAH, also marketed as VEOZA in Europe, contains fezolinetant, a nonhormonal neurokinin-3 receptor antagonist for menopausal vasomotor symptoms. IZERVAY (avacincaptad pegol) is a complement C5 inhibitor administered by injection into the eye for geographic atrophy secondary to age-related macular degeneration. PROGRAF (tacrolimus) is an immunosuppressant used to help prevent organ-transplant rejection. Product names and approved uses vary by market.[10][11][12][13][14][15][16] [6][7][8][9][10][11][12][13][14][15][16]
Geographic presence
Astellas Pharma is headquartered in Tokyo, Japan. Its geographic reporting distinguishes Japan, the United States, China, Established Markets and International Markets. In FY2024, it reported 13,643 full-time employees across those areas: 4,105 in Japan, 3,487 in the United States, 3,172 in Established Markets, 1,144 in China and 1,735 in International Markets. These are employee categories, not a breakdown of sales.[17][5]
The company maintains corporate offices, research facilities and manufacturing sites across its global network. Its research footprint includes sites in Japan and the United States, including Tsukuba, Cambridge, Massachusetts, and South San Francisco.[18][19] [17][5][18][19]
Business segments
Astellas reports a single operating segment, its pharmaceutical business, so it does not report separate segment revenue for therapeutic areas or products. The pharmaceutical business accounts for 100% of reported revenue.[20]
A separate geographic sales breakdown for FY2024, ended March 2025, shows the United States at ¥866.4 billion (approximately 45% of total revenue), Established Markets at ¥485.4 billion (25%), Japan at ¥267.0 billion (14%), International Markets at ¥203.5 billion (11%), and China at ¥78.3 billion (4%). Established Markets includes Europe and Canada; International Markets includes countries across Latin America, the Middle East, Africa and Asia. These are sales regions, not reportable business segments. The listed regional amounts do not fully reconcile to total revenue of ¥1,912.3 billion, so their percentages should be read as approximate shares rather than a complete allocation.[21] [22][22][22][22][22][22][20][21]
Company history
Astellas Pharma was established on April 1, 2005, through the merger of two Japanese drugmakers: Fujisawa Pharmaceutical, whose origins date to 1894, and Yamanouchi Pharmaceutical, founded in 1923. Before the merger, Fujisawa had introduced the immunosuppressant Prograf in Japan in 1993.[2][23]
Astellas expanded through acquisitions, completing its purchase of OSI Pharmaceuticals in 2010. In 2012, it and its partner Medivation made the prostate-cancer medicine Xtandi available in the United States. Later acquisitions included Ganymed Pharmaceuticals in 2016 and the gene-therapy company Audentes Therapeutics in 2020.[24][25][26][27] [2][23][24][25][26][27]
Sources
- www.astellas.com[1]
- www.astellas.com[2]
- www.astellas.com[3]
- www.astellas.com[4]
- www.astellas.com[5]
- www.xtandi.com[6]
- www.xospata.com[7]
- www.padcev.com[8]
- www.vyloy.com[9]
- www.myrbetriq.com[10]
- www.ema.europa.eu[11]
- www.veozah.com[12]
- www.ema.europa.eu[13]
- www.izervay.com[14]
- dailymed.nlm.nih.gov[15]
- www.astellas.com[16]
- www.astellas.com[17]
- www.astellas.com[18]
- www.astellas.com[19]
- www.astellas.com[20]
- www.astellas.com[21]
- ASTELLAS PHARMA INC — Presentation (2025 Q 1)[22]
- newsroom.astellas.com[23]
- newsroom.astellas.com[24]
- newsroom.astellas.com[25]
- newsroom.astellas.com[26]
- newsroom.astellas.com[27]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore ASTELLAS PHARMA INC in Finbar ↗